TESTS
European patent · EP2856161 · In force
Register entry
- Publication number
- EP2856161
- Application number
- EP13734141
- Kind
- European patent with effect for Switzerland and Liechtenstein
- Status
- In force
- Specification
- Granted
- Filed
- May 31, 2013
- Published
- Apr 8, 2015
- Granted
- Apr 18, 2018
- Protection ends at the latest
- May 30, 2033
- Next annual fee due
- May 31, 2027
- IPC classes
- G01N 33/542 (2006.01)C07K 14/72 (2006.01)G01N 33/566 (2006.01)
- Priority
- US 201261654265 P 01.06.2012
- PCT application
- PCT/GB2013/051464 31.05.2013
- PCT publication
- WO2013/179062 05.12.2013
- Filing language
- English
- Source
- Swissreg
History
What the Federal Institute of Intellectual Property published about this title, newest first.
- Jun 1, 2026
Change
Published in Swissreg on 01.06.2026
- Jun 1, 2025
Change
Published in Swissreg on 01.06.2025
- Jul 5, 2024
Address changed
- Owner
- Heptares Therapeutics Limited, BioPark, Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AX, United Kingdom → Nxera Pharma UK Limited, Granta Park, Great Abington, Cambridge, Cambridgeshire CB21 6DG, United Kingdom
Published in Swissreg on 05.07.2024
- Jun 2, 2024
Change
Published in Swissreg on 02.06.2024
- Jun 2, 2023
Change
Published in Swissreg on 02.06.2023
- Jun 19, 2018
Agent entered
- Representative
- Isler & Pedrazzini AG, Postfach 1772, 8027 Zürich
Published in Swissreg on 19.06.2018
- Apr 18, 2018
Granted
Published in Swissreg on 18.04.2018
Parties
Inventor
Welwyn Garden City Hertfordshire AL7 3AX, GB
Welwyn Garden City Hertfordshire AL7 3AX, GB
Welwyn Garden City Hertfordshire AL7 3AX, GB
The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.